- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07933042
A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)
TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds
The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.
Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.
Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: TOBY ATLAS Study Team
- Numero di telefono: 309-592-8898
- Email: info@toby.health
Backup dei contatti dello studio
- Nome: TOBY ATLAS Study Team
- Email: press@toby.health
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.
Descrizione
Inclusion Criteria:
- Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
- Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
- Medical records available for the reference standard.
- Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.
Exclusion Criteria:
- Any exclusion stated in the applicable disease specification.
- Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
- Current pregnancy, imprisonment, or inability to consent for oneself (consented route).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_CONTROL
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Target disease cases
Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified. |
|
Controls
Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical performance of each locked assay
Lasso di tempo: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Paired comparison with available standard-of-care tests
Lasso di tempo: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assay performance by subgroup and signal origin
Lasso di tempo: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Protocol-conforming specimens with final reference-standard classification
Lasso di tempo: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type. |
From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Candidate assays advanced to validation
Lasso di tempo: From study start through study completion, estimated up to 5 years
|
Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan. |
From study start through study completion, estimated up to 5 years
|
|
Exploratory prognostic and simulated clinical and economic outcomes
Lasso di tempo: Up to 5 years after specimen collection, where follow-up is permitted and available
|
Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care. |
Up to 5 years after specimen collection, where follow-up is permitted and available
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- TOBY-ATLAS-001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
There is currently no plan to make individual participant data available to other researchers.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .